Spots Global Cancer Trial Database for proximal urethral cancer
Every month we try and update this database with for proximal urethral cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | NCT00478361 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | Gemcitabine hyd... Paclitaxel Doxorubicin hyd... Pegfilgrastim | - | M.D. Anderson Cancer Center | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | NCT01611662 | Distal Urethral... Proximal Urethr... Squamous Cell C... Stage II Bladde... Stage III Bladd... Urethral Cancer... | gemcitabine hyd... cisplatin therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | NCT00021099 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | NCT00003704 | Cancer | capecitabine radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | NCT01611662 | Distal Urethral... Proximal Urethr... Squamous Cell C... Stage II Bladde... Stage III Bladd... Urethral Cancer... | gemcitabine hyd... cisplatin therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00083213 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Afatinib in Advanced Refractory Urothelial Cancer | NCT02122172 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer | afatinib dimale... laboratory biom... | 18 Years - | University of Chicago | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | NCT00003704 | Cancer | capecitabine radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| Afatinib in Advanced Refractory Urothelial Cancer | NCT02122172 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer | afatinib dimale... laboratory biom... | 18 Years - | University of Chicago | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer | NCT00002684 | Bladder Cancer Urethral Cancer | cisplatin ifosfamide paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | NCT00407485 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Squamous Cell C... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ziv-aflibercept pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | NCT00004856 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | NCT00003704 | Cancer | capecitabine radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
